News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
Views & Analysis To you it's a document; to me it's my life Proactive and included patients can help clinical trial retention.
News Merrimack goes back to drawing board with $1bn Ipsen sell-of... Merrimack sells off Onivyde and generic cancer drug
Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
News FDA starts review of Regeneron's drug for rare disease FOP Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
